“Together for health. Stand with science,” a rallying cry for the upcoming World Health Day 2026, encapsulates the urgent call for global collaboration in health protection. As the world prepares for this significant day on April 7, 2026, the theme highlights the critical role of scientific cooperation in addressing health challenges.

This year’s campaign, which focuses on the One Health approach, aims to unite efforts across various sectors to safeguard public health. The International One Health Summit will take place on the same day, bringing together nearly 800 scientific institutions from over 80 countries.

In a statement, organizers emphasized, “We call on governments, scientists, health workers, partners, and the public to stand with science to protect lives, rebuild trust, and secure a healthier future.” This call to action underscores the importance of collective efforts in the face of ongoing health crises.

The inaugural Global Forum of WHO Collaborating Centres will also occur from April 7 to 9, 2026, further enhancing the dialogue on health issues. With nearly 800 institutions participating, the forum is set to be a landmark event in the global health landscape.

World Health Day, celebrated annually on April 7, serves as a reminder of the ongoing challenges and the need for a unified response. The 2026 theme resonates particularly in light of recent global health emergencies, emphasizing the necessity of scientific backing in decision-making processes.

As the date approaches, the campaign invites participation through social media hashtags #StandWithScience and #WorldHealthDay, encouraging individuals and organizations to join the movement. The emphasis on scientific collaboration is more crucial than ever, as the world grapples with complex health issues.

Details remain unconfirmed regarding specific events or speakers at the Global Forum, but the anticipation is building as stakeholders prepare for a robust exchange of ideas and strategies.

With the backdrop of the ongoing pandemic and other health challenges, World Health Day 2026 is poised to be a pivotal moment for global health advocacy. The collective efforts of scientists, health workers, and the public will be essential in shaping a healthier future.

The post World Health Day: Together for Health, Stand with Science appeared first on berightnews.

AIIMS Mangalagiri has reached a significant milestone by conferring degrees on 49 MBBS graduates, along with five MD/MS postgraduate students and four Post-Doctoral Certificate Course students. This achievement highlights the institution’s growth since the MBBS course began in 2018, which started with an initial intake of 50 students and has now expanded to 748 students, with an annual intake of 125.

The hospital has also completed an impressive 31 lakh outpatient department (OPD) consultations, showcasing its vital role in the healthcare landscape of Andhra Pradesh. Currently, AIIMS Mangalagiri sees a daily patient footfall of around 3,500 to 4,000, reflecting the increasing demand for its services.

In a groundbreaking development, AIIMS Mangalagiri has installed a Nucleic Acid Amplification Testing (NAAT) system, the first of its kind among all AIIMS in South India. This advanced system, which cost approximately ₹1.73 crore, enhances diagnostic capabilities by detecting viral RNA/DNA with high sensitivity, allowing for early identification of infections such as HIV, Hepatitis B, and Hepatitis C.

Union Minister Anupriya Patel emphasized the government’s commitment to the medical sector, stating, “The Union government under the leadership of Prime Minister Narendra Modi is giving utmost priority to the medical sector.” This statement underscores the ongoing efforts to improve healthcare access and quality for the population.

Ahanthem Singh, a representative from AIIMS Mangalagiri, noted that the NAAT system significantly enhances safety by reducing the diagnostic window period. This advancement is expected to improve patient outcomes and streamline the testing process.

As AIIMS Mangalagiri continues to evolve, observers anticipate further developments in medical education and patient care. The institution’s focus on innovation and quality healthcare is likely to set a benchmark for other medical colleges in the region.

With these advancements, AIIMS Mangalagiri is poised to play a crucial role in addressing the healthcare needs of the community, ensuring that quality medical education and services are accessible to all.

The future looks promising for AIIMS Mangalagiri as it continues to expand its capabilities and enhance its offerings to students and patients alike.

The post AIIMS Mangalagiri Achieves Milestone with Degree Conferral appeared first on berightnews.

The BA.3.2 variant, commonly referred to as the Cicada variant, was first identified in South Africa in November 2024. As a descendent of the BA.3 omicron subvariant that emerged in 2022, it has quickly gained attention due to its rapid spread across various countries. Currently, the Cicada variant has been detected in over 20 countries, with a notable rise in cases reported in the United States, where it has been observed in 25 states.

Health experts are closely monitoring the situation as the Cicada variant carries approximately 70 to 75 mutations in its spike protein. This significant number of mutations raises questions about its transmissibility and the effectiveness of existing vaccines. However, initial evidence suggests that the BA.3.2 variant does not cause more severe illness compared to earlier strains of COVID-19.

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those of previous COVID-19 strains, leading health authorities to emphasize the importance of staying vigilant.

Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” Most cases appear to be mild to moderate, resembling flu-like illness, particularly among vaccinated individuals. Experts highlight that most cases can be managed at home with rest and hydration.

Despite the presence of multiple mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Health authorities continue to recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the spread of the variant.

As the Cicada variant spreads, health experts have noted that symptoms remain largely consistent with previous Omicron strains, with no new or unusual signs reported so far. However, there are concerns regarding the potential impact of the variant on vaccine efficacy due to its mutations. Some experts suggest that the current COVID-19 vaccines may not be as effective against it.

Health authorities are actively monitoring the BA.3.2 variant due to its rising presence. Observers anticipate that continued vigilance and adherence to public health guidelines will be crucial in managing the spread of this variant. As the situation evolves, details remain unconfirmed, and further updates will be essential for public awareness and safety.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on berightnews.

The Kerala government has reportedly submitted multiple proposals over the years for establishing an AIIMS, a move aimed at addressing the state’s pressing healthcare needs. Despite these efforts, the Union government has yet to approve the proposal, leaving many in the state concerned about the future of healthcare infrastructure.

In 2025, the Kerala government identified land in Kinalur, Kozhikode, for the proposed AIIMS project. However, the Centre has not provided a timeline for when the approval might come, leading to frustration among local leaders and citizens alike.

Union Minister of State for Health and Family Welfare Prataprao Jadhav confirmed, “The proposal for establishing AIIMS in Kerala has not been approved,” highlighting the ongoing uncertainty surrounding the project.

The demand for an AIIMS in Kerala has become a political issue ahead of the state Assembly elections, with Congress MPs Kodikunnil Suresh and Adoor Prakash vocalizing their concerns regarding the lack of progress. They argue that the absence of such a facility is detrimental to the state’s healthcare system.

In 2016, several potential locations for AIIMS in Kerala were identified and proposed, but the journey toward realization has been fraught with delays. In 2019, the Union Health Ministry sought ‘in-principle’ approval from the Finance Ministry, yet no further steps have been taken since then.

Observers note that the absence of an AIIMS in Kerala is not just a matter of healthcare but also a significant political issue, especially as the state prepares for elections. The demand for improved healthcare services is intensifying, and the lack of an AIIMS is seen as a failure to meet these needs.

Details remain unconfirmed regarding the reasons for the delay in approval of the AIIMS proposal, as well as the timeline for its implementation. The Kerala government continues to advocate for the establishment of this critical healthcare facility, emphasizing its importance for the state’s residents.

As the political landscape heats up, the pressure on the Union government to act on the AIIMS proposal is likely to increase, with many watching closely for any developments.

The post AIIMS Proposal in Kerala Faces Continued Delays appeared first on berightnews.

The emergence of the Cicada COVID variant has sparked urgent health concerns as it spreads globally, including in India. This variant, classified as BA.3.2 and part of the Omicron family, was first identified in South Africa in November 2024.

With over 70 mutations compared to the original Wuhan strain, the Cicada variant carries approximately 75 mutations in total, with more than 50 of these located in the spike protein. This raises questions about its potential to evade immunity from previous infections or vaccinations.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. However, it has not been confirmed to cause more severe illness than previous variants.

As of now, the variant has been detected in 22 countries, with the first confirmed case in the United States reported in June 2025. By January 2026, three patients in the U.S. had been confirmed to have contracted the variant, all of whom recovered.

Health officials are closely monitoring the situation. Dr. Robert Hopkins Jr. noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” The CDC emphasized the importance of tracking the spread of BA.3.2 to gather valuable information regarding its potential impact on immunity.

In India, the detection of the Cicada variant raises alarms as health authorities prepare to respond to any potential outbreaks. The situation is being closely monitored, and public health measures may be adjusted accordingly.

As the world grapples with the ongoing pandemic, the emergence of new variants like Cicada underscores the need for continued vigilance. Details remain unconfirmed regarding the variant’s severity and its implications for public health.

The post Cicada COVID Variant in India Raises Concerns Amid Global Spread appeared first on berightnews.

The Kerala government has reportedly submitted multiple proposals over the years for establishing an AIIMS. Despite these efforts, the Union government has not approved the proposal, leaving the state’s healthcare needs unaddressed.

In 2025, the Kerala government identified land in Kinalur, Kozhikode, for the proposed AIIMS project. However, the Centre has not provided a timeline for the approval of this critical healthcare initiative.

Union Minister of State for Health and Family Welfare Prataprao Jadhav confirmed, “The proposal for establishing AIIMS in Kerala has not been approved.” This statement underscores the ongoing challenges faced by the state in securing necessary healthcare infrastructure.

The absence of an AIIMS in Kerala has become a political issue ahead of the state Assembly elections, with Congress MPs Kodikunnil Suresh and Adoor Prakash vocalizing their concerns. They argue that the demand for an AIIMS is directly linked to the state’s pressing healthcare needs.

In 2016, several potential locations for AIIMS in Kerala were identified and proposed, yet progress has stalled. By 2019, the Union Health Ministry sought ‘in-principle’ approval from the Finance Ministry, but no further developments have been reported.

Details remain unconfirmed regarding the reasons for the delay in approval of the AIIMS proposal. Observers are concerned that the lack of action could impact the healthcare landscape in Kerala significantly.

The political ramifications of this issue are palpable, as the demand for an AIIMS continues to resonate with the electorate. As the state approaches elections, the focus on healthcare infrastructure is likely to intensify.

With the Centre’s silence on the approval timeline, the future of the AIIMS project in Kerala remains uncertain. The Kerala government is expected to continue advocating for the establishment of this vital institution.

As discussions unfold, the healthcare needs of the state remain a priority, with many hoping for a resolution that addresses the longstanding demand for an AIIMS.

The situation is evolving, and stakeholders are closely monitoring developments as the political landscape shifts in the lead-up to the elections.

The post AIIMS Proposal in Kerala Remains Unapproved Amid Political Tensions appeared first on berightnews.

Sun Pharmaceutical Industries Limited, a leader in the pharmaceutical industry, is dedicated to advancing patient care in areas such as psoriasis, alopecia areata, and acne. At the 2026 AAD Annual Meeting held in Denver, Colorado, Sun Pharma presented 14 abstracts, highlighting its commitment to dermatology and immunology.

Among the key developments, ILUMYA, which targets moderate-to-severe plaque psoriasis and nail psoriasis, continues to show promise in improving patient outcomes. Additionally, LEQSELVI is being utilized for the treatment of severe alopecia areata, while WINLEVI is indicated for acne vulgaris and is often used in combination therapies.

However, not all news was positive; the Phase II FLASH study for Fibromun did not meet its primary endpoint for progression-free survival (PFS). This outcome raises questions about the future direction of this treatment.

On a more encouraging note, Nidlegy achieved complete pathological responses in 52.6% of patients in the Phase II ‘Duncan’ study, demonstrating significant efficacy. Furthermore, the GLIOSTELLA study in late-line glioblastoma has completed enrollment in the U.S., marking a critical step forward in cancer research.

Following the withdrawal of a prior Marketing Authorization Application in 2025, Sun Pharma is preparing a new submission for Nidlegy, reflecting its ongoing commitment to bringing innovative therapies to market.

Dr. Ahmad Naim commented on the presentations, stating, “The data we are presenting at AAD underscore our commitment to advancing dermatology and immunology through meaningful science – spanning not only clinical efficacy and safety, but also how these therapies perform over time and in real-world practice.” This statement reinforces the company’s focus on long-term patient care.

As the industry watches closely, observers anticipate further developments from Sun Pharma, particularly regarding the outcomes of ongoing studies and the potential impact of new submissions on the market.

Details remain unconfirmed regarding the future of Fibromun, but the company’s proactive approach suggests a determination to refine its strategies and improve patient outcomes across its product range.

The post Sun Pharma Advances Dermatology Research at AAD Annual Meeting appeared first on berightnews.

In the wake of rising global tensions and concerns over supply chains, the Indian government has taken a firm stance regarding the possibility of a lockdown. Union Minister Hardeep Singh Puri and Finance Minister Nirmala Sitharaman have both publicly stated that there is no proposal for a lockdown in India, dismissing rumors as baseless. This reassurance comes as a relief to many who vividly remember the nationwide lockdown that was announced on March 24, 2020, in response to the Covid-19 pandemic.

Before this recent clarification, there was a surge in public anxiety, driven by memories of the drastic measures taken during the pandemic. As of February 2, 2026, India reported only seven active Covid-19 infections, indicating a significant decline in cases. However, the ongoing conflict in West Asia has raised concerns about potential disruptions in energy supplies and essential commodities, prompting citizens to search for information about a possible lockdown.

Prime Minister Narendra Modi has also weighed in on the situation, warning of serious consequences if global disruptions persist due to the war. He emphasized the importance of ensuring uninterrupted availability of fuel and energy supplies, highlighting the critical nature of the Strait of Hormuz, which is a vital route for nearly 20% of the world’s oil and gas supplies.

In response to these challenges, the Indian government is closely monitoring developments across energy and supply chains. Hardeep Singh Puri stated, “The global situation remains in flux, and we are closely monitoring developments.” This proactive approach aims to mitigate any potential impact on the Indian economy and ensure that essential services remain operational.

Nirmala Sitharaman reiterated the government’s commitment to avoiding a repeat of the past lockdown, stating, “There shall not be any lockdown.” This statement is crucial for maintaining public confidence as citizens navigate the uncertainties posed by global events. The government is focused on building resilience, as Modi noted, “India is therefore accelerating all the resilience-building measures that have been undertaken over the past years.”

Despite the reassurances from government officials, the spike in searches for ‘lockdown in India’ indicates that the public remains wary. The memories of the 2020 lockdown are still fresh, and the fear of similar restrictions can easily resurface, especially in light of the ongoing global crises.

As the situation evolves, the Indian government continues to emphasize its commitment to transparency and public safety. While the current status shows no immediate threat of a lockdown, the landscape remains dynamic, and officials are prepared to respond to any changes. Details remain unconfirmed regarding future measures, but the government’s current stance is clear: India will not revert to the lockdown measures of the past.

The post India Lockdown: Government Dismisses Rumors Amid Global Tensions appeared first on berightnews.

The central question surrounding the recent Nipah virus outbreak in Kerala is: how can health authorities effectively manage this persistent threat? The answer lies in urgent surveillance and public awareness efforts, as Kerala has witnessed multiple outbreaks since the virus was first identified in Malaysia in 1999.

Nipah virus, transmitted to humans through infected animals or contaminated food, has no licensed medicines or vaccines available. Kerala’s first outbreak occurred in May 2018, with 18 confirmed cases and 17 deaths reported. Since then, the state has experienced further outbreaks, including a notable incident in 2023.

As of 2026, Kerala has reported two deaths from Nipah virus, with recent cases linked to health-care workers. Alarmingly, two nurses in West Bengal have slipped into comas due to the virus, raising concerns about its spread beyond Kerala.

Current data indicates that 700 individuals are on the contact list for Nipah virus risk, with 77 categorized as high-risk. The fruiting season in Kerala, around April, correlates with increased Nipah virus cases, emphasizing the need for timely public health interventions.

Scientists warn that the danger of Nipah virus lies in its periodic and lethal nature, urging for improved surveillance and research funding. “Surveillance is activated too late, research funding is sporadic, and preparedness is episodic,” experts note.

In response to the ongoing threat, awareness campaigns targeting children are planned in Kerala, particularly due to past infections in that age group. Health officials recommend avoiding fruits lying on the ground or those bitten by bats, washing and peeling fruits before consumption, and steering clear of bat roosts.

Despite these measures, the effectiveness of surveillance and preparedness remains under scrutiny, with criticisms highlighting poor and episodic responses to outbreaks. The recent surge in cases underscores the urgent need for a coordinated approach to manage Nipah virus risks.

As the situation develops, health authorities continue to monitor the outbreak closely. Details remain unconfirmed regarding the full extent of the current outbreak, but the implications for public health are significant.

The post Nipah Virus Outbreak in Kerala Raises Urgent Health Concerns appeared first on berightnews.

The cicada COVID variant, known as BA.3.2, is causing alarm as it spreads across the United States. Detected in at least 25 states as of February 2026, this heavily mutated variant may evade immunity from vaccines and prior infections, raising significant public health concerns.

First identified in South Africa in November 2024, BA.3.2 has 70 to 75 mutations in its spike protein, which could reduce the effectiveness of current vaccines. Andrew Pekosz, Ph.D., noted, “It has a lot of mutations that may cause it to look different to your immune system.” This variant is classified as a ‘variant under monitoring’ by the World Health Organization since December 2025.

As of now, BA.3.2 is not causing more severe disease or hospitalizations compared to previous strains, according to Dr. Adolfo García-Sastre. However, the variant’s ability to spread primarily through respiratory particles and prolonged face-to-face interactions poses a risk for increased transmission.

In Denmark, Germany, and the Netherlands, approximately 30% of COVID-19 cases are attributed to BA.3.2. Additionally, a nationwide analysis of sewage samples indicated that 3.7% were positive for this variant, suggesting a broader presence in the community.

Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, and loss of smell or taste, among others. Vaccination remains crucial, as it is expected to continue providing protection against severe disease, although its effectiveness against infection may be diminished.

BA.3.2 was first detected in the U.S. in June 2025, in a traveler returning from the Netherlands. The name ‘cicada’ reflects the variant’s unusual emergence pattern, reminiscent of the insect’s lifecycle.

Despite the ongoing spread, health officials emphasize that vaccination is still vital in limiting cases. Pekosz stated, “Vaccination is still going to help limit cases.” However, uncertainties remain regarding the exact reasons for the resurgence of BA.3.2 and its long-term impact on public health. Details remain unconfirmed.

The post Cicada COVID Variant BA.3.2 Raises Concerns in the U.S. appeared first on berightnews.